復星醫藥(02196.HK)擬出資1900萬美元認購MGB Ⅲ 基金份額
格隆匯 2 月 1日丨復星醫藥(02196.HK)公吿,上海復星醫藥(集團)股份有限公司(以下簡稱“公司”)控股子公司復星實業(香港)有限公司(以下簡稱“復星實業”)擬作為有限合夥人出資1900萬美元認購Mass General Brigham Fund Ⅲ,L.P.(以下簡稱“MGBⅢ”或“目標基金”)的等值份額(以下簡稱“本次投資”)。
2021年2月1日,復星實業與MGBⅢ普通合夥人Mass General Brigham GPIII,LLC簽署《Mass General Brigham Fund Ⅲ,L.P.Subscription Agreement》(即“《目標基金認購協議》”)等,復星實業擬作為有限合夥人出資1900萬美元認購目標基金首輪募集中的等值份額(以下簡稱“本次投資”),認繳份額約佔目標基金首輪募集總額的10.2%(目標基金計劃募集總額為25,000萬美元,其中首輪計劃募集總額為18,700萬美元;復星實業實際持有目標基金的份額比例以該基金最終募集完成情況為準)。復星實業擬以自籌資金支付本次投資對價。
目標基金擬以研究成果可能解決醫療缺口的大健康領域的種子公司及早期公司作為投資組合,包括但不限於製藥、生物技術和醫療器械公司等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.